Venture Capital Investment Trends in Pharma – Q2 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
Scope
This report provides an overview of VC investment activity globally in Q2 2026 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q2 2026 in the Pharma sector.
Key Highlights
In Q2 2026, global pharma investment totaled $9.1 billion, up 16.7% from Q1 2026. Deal volume also edged up 0.6% to 178 transactions. Oncology emerged as the top therapy area with 79 deals backed by 265 investors.
Reasons to Buy
Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Newlimit
Ollin Biosciences
CellCentric
Osanni Bio
Bionyra Pharma
Windward Bio
Sidewinder Therapeutics
Beren Therapeutics
Beeline Medicines
Stipple Bio
Contraline
Terremoto Biosciences
Biossil
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports